Wall Street analysts expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to post $0.07 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for BioDelivery Sciences International’s earnings, with estimates ranging from $0.07 to $0.08. BioDelivery Sciences International reported earnings per share of $0.09 in the same quarter last year, which indicates a negative year over year growth rate of 22.2%. The company is scheduled to report its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that BioDelivery Sciences International will report full year earnings of $0.27 per share for the current year, with EPS estimates ranging from $0.22 to $0.29. For the next financial year, analysts forecast that the company will post earnings of $0.46 per share, with EPS estimates ranging from $0.34 to $0.59. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, August 3rd. The specialty pharmaceutical company reported $0.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.04. The company had revenue of $41.44 million for the quarter, compared to analyst estimates of $42.02 million. BioDelivery Sciences International had a net margin of 20.65% and a return on equity of 31.75%.
Shares of NASDAQ:BDSI opened at $3.99 on Wednesday. The company has a market capitalization of $393.41 million, a PE ratio of 12.09 and a beta of 0.70. BioDelivery Sciences International has a 52 week low of $3.04 and a 52 week high of $4.99. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.78 and a current ratio of 3.07. The company has a 50 day moving average price of $3.79 and a two-hundred day moving average price of $3.68.
Institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its stake in shares of BioDelivery Sciences International by 7.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 475,700 shares of the specialty pharmaceutical company’s stock valued at $1,998,000 after acquiring an additional 32,645 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of BioDelivery Sciences International by 199.6% in the 1st quarter. Victory Capital Management Inc. now owns 47,706 shares of the specialty pharmaceutical company’s stock valued at $187,000 after acquiring an additional 31,784 shares in the last quarter. Black Swift Group LLC bought a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at $137,000. IndexIQ Advisors LLC bought a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at $418,000. Finally, Alps Advisors Inc. bought a new stake in shares of BioDelivery Sciences International in the 1st quarter valued at $352,000. Hedge funds and other institutional investors own 60.02% of the company’s stock.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC.
Featured Story: Trading Ex-Dividend Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.